NORTHERN TRUST CORP - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,646,208
-55.6%
1,248,212
-0.3%
0.00%0.0%
Q2 2023$5,961,714
+33.2%
1,252,461
+59.5%
0.00%0.0%
Q1 2023$4,476,153
-41.9%
785,290
+2.9%
0.00%
-50.0%
Q4 2022$7,703,069
-55.2%
763,436
-0.6%
0.00%
-50.0%
Q3 2022$17,204,000
-10.5%
767,700
-1.1%
0.00%0.0%
Q2 2022$19,227,000
-36.4%
775,907
-0.5%
0.00%
-20.0%
Q1 2022$30,234,000
-36.4%
779,832
-4.0%
0.01%
-37.5%
Q4 2021$47,517,000
-2.6%
812,107
-1.4%
0.01%
-11.1%
Q3 2021$48,802,000
-36.4%
823,397
-6.9%
0.01%
-35.7%
Q2 2021$76,781,000
+5.6%
884,680
+0.3%
0.01%0.0%
Q1 2021$72,732,000
-10.5%
882,122
-1.3%
0.01%
-12.5%
Q4 2020$81,234,000
+121.5%
893,368
-2.6%
0.02%
+100.0%
Q3 2020$36,677,000
+21.7%
917,606
+4.4%
0.01%
+14.3%
Q2 2020$30,148,000
+69.7%
878,695
+9.9%
0.01%
+40.0%
Q1 2020$17,762,000
+14.8%
799,720
+1.1%
0.01%
+66.7%
Q4 2019$15,473,000
+43.1%
790,630
+13.5%
0.00%0.0%
Q3 2019$10,813,000
-29.2%
696,320
-7.5%
0.00%
-25.0%
Q2 2019$15,280,000
+16.0%
752,696
+0.4%
0.00%
+33.3%
Q1 2019$13,167,000
+39.5%
749,372
+1.9%
0.00%0.0%
Q4 2018$9,437,000
-7.2%
735,512
+17.8%
0.00%
+50.0%
Q3 2018$10,174,000
+57.9%
624,576
+9.9%
0.00%0.0%
Q2 2018$6,444,000
+32.9%
568,272
+14.4%
0.00%
+100.0%
Q1 2018$4,850,000
+104.3%
496,919
+27.9%
0.00%0.0%
Q4 2017$2,374,000
+52.6%
388,416
-1.2%
0.00%
Q3 2017$1,556,000
+30.4%
392,950
+6.7%
0.00%
Q2 2017$1,193,000
+659.9%
368,208
+968.7%
0.00%
Q1 2017$157,000
+57.0%
34,455
-13.4%
0.00%
Q4 2016$100,000
-17.4%
39,773
+3.0%
0.00%
Q3 2016$121,000
+181.4%
38,625
+51.3%
0.00%
Q2 2016$43,000
-6.5%
25,5310.0%0.00%
Q1 2016$46,000
-46.5%
25,5310.0%0.00%
Q4 2015$86,000
-36.8%
25,5310.0%0.00%
Q3 2015$136,000
-28.8%
25,531
-13.3%
0.00%
Q2 2015$191,00029,4640.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$131,006,00024.77%
Redmile Group, LLC 12,957,222$502,351,00015.68%
Grosvenor Holdings, L.L.C. 1,037,256$40,214,0007.85%
Casdin Capital, LLC 3,400,000$131,818,0005.91%
Ally Bridge Group (NY) LLC 181,500$7,037,0005.22%
DAFNA Capital Management LLC 500,930$19,421,0005.06%
Deep Track Capital, LP 2,000,000$77,540,0004.97%
Artal Group S.A. 2,000,000$77,540,0003.25%
Tri Locum Partners LP 190,345$7,380,0002.88%
ARK Investment Management 10,988,182$426,012,0001.78%
View complete list of FATE THERAPEUTICS INC shareholders